

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number 10/671,883  
 Filing Date 09/29/2003  
 First Named Inventor Xiaolei Yu  
 Group Art Unit 1645  
 Examiner Name Unassigned  
 Attorney Docket Number 035642-0105

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
SP	A1	OUABDESSELAM et al., "Detection of gyrA and gyrB Mutations in Quinolone-Resistant Clinical Isolates of Escherichia coli by Single-Strand Conformational Polymorphism Analysis and Determination of Levels of Resistance Conferred by Two Different Single gyrA Mutations," (1995), pp. 1667-1670, vol. 39, No. 8, Antimicrobial Agents and Chemotherapy.	
SP	A2	QIANG et al., "Use of a Rapid Mismatch PCR Method to Detect gyrA and parC Mutations in Ciprofloxacin-resistant Clinical Isolates of Escherichia coli," (2002), pp. 549-552, vol. 49, Journal of Antimicrobial Chemotherapy.	
SP	A3	HOOPER et al., "Mechanisms of Action of and Resistance to Ciprofloxacin," (1987), pp. 12-20, vol. 82 (suppl. 4A), The American Journal of Medicine.	

Examiner Signature

/Steven Pohnert/ (07/14/2006)

Date Considered

07/14/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.